DHL Supply Chain Italy, a company of the Deutsche Post Dhl Group, inaugurates, with an investment of three million euros, the Dhl Bio Pharma Hub, built within the Settala (Milan) site, dedicated to companies in the Hospital & Specialty Pharma sector. A team specialized in the management of sensitive products that require temperature-controlled logistics operates within the new hub. The new center has an area of 6 thousand square meters and the new “cold store” guarantees a 360 ° management of the biotechnological products transported and stored.
«The drug in each step – explains the company in a note – is handled in a temperature environment with a constant range of 2-8 ° C, preventing the risk of thermal excursions. The Hub also integrates solutions for the management of multi-temperature situations (down to -20 ° C and -80 ° C) for vaccines and frontier therapies. Innovative technologies, such as serialization, guarantee multiple benefits: automation of the serialization process, tracking of each individual drug package up to its destination, digitization of data, immediate availability of the unique identifier to be provided to the competent authorities in the event of product recall ” .
Loading…
The site has a storage capacity of up to 8,000 pallet spaces at 2-8 ° C and handles over 41 million packages of specialist and biotechnological drugs. “In a moment of great transformation in the sector, characterized by increasingly sensitive and delicate therapies, we decided to focus on a project dedicated to Biotech and to all products that need a very specialized cold chain. The new structure is part of the growth path of our company – declared Antonio Lombardo, President and CEO of DHL Supply Chain Italy -, not only from an economic point of view but above all in the evolution of the challenges we face. Biotech and advanced therapies represent a completely new approach to treatment and require adequate methods and procedures also from a logistical point of view. From research to production, to regulations, to access to the market, the entire plant must be revised to better manage the potential of the new line and logistics is no exception ».
«Biotech increasingly represents a significant share of drugs in development. Already today, globally, 50% of products in clinical trials derive from biotechnological processes and OECD estimates tell us that in 2030 80% of pharmaceutical products will be biotech. This is why it becomes essential to combine precision medicine, such as that using biotech drugs, with precision logistics. Integrity of the cold chain, high security, traceability and serialization of each unit, the ability to manage storage and transport at different temperatures are already key elements for patient safety today and will increasingly be so in the future “- added Riccardo Palmisano President of Assobiotec, the National Association for the development of biotechnologies which is part of Federchimica, which participated in the inauguration of the new hub.